Diagnamed Holdings Corp. Logo

Diagnamed Holdings Corp.

DMED.CN

(0.8)
Stock Price

0,03 CAD

-301.81% ROA

-414.07% ROE

-1.31x PER

Market Cap.

400.263,00 CAD

0% DER

0% Yield

0% NPM

Diagnamed Holdings Corp. Stock Analysis

Diagnamed Holdings Corp. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Diagnamed Holdings Corp. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

3 ROE

The stock's ROE indicates a negative return (-102.41%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-80.25%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 PBV

The stock's elevated P/BV ratio (4.5x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Diagnamed Holdings Corp. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Diagnamed Holdings Corp. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Hold

Diagnamed Holdings Corp. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Diagnamed Holdings Corp. Revenue
Year Revenue Growth
2021 0
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Diagnamed Holdings Corp. Research and Development Expenses
Year Research and Development Expenses Growth
2021 201.771
2022 562.859 64.15%
2023 334.908 -68.06%
2023 514.749 34.94%
2024 311.552 -65.22%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Diagnamed Holdings Corp. General and Administrative Expenses
Year General and Administrative Expenses Growth
2021 481.897
2022 572.834 15.87%
2023 515.432 -11.14%
2023 652.564 21.01%
2024 313.420 -108.21%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Diagnamed Holdings Corp. EBITDA
Year EBITDA Growth
2021 580.480
2022 -1.138.952 150.97%
2023 -924.644 -23.18%
2023 -100.271 -822.14%
2024 -668.160 84.99%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Diagnamed Holdings Corp. Gross Profit
Year Gross Profit Growth
2021 -16
2022 -25 33.33%
2023 0 0%
2023 0 0%
2024 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Diagnamed Holdings Corp. Net Profit
Year Net Profit Growth
2021 -1.947.816
2022 -1.132.434 -72%
2023 -776.036 -45.93%
2023 -1.277.935 39.27%
2024 -882.488 -44.81%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Diagnamed Holdings Corp. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2021 0
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Diagnamed Holdings Corp. Free Cashflow
Year Free Cashflow Growth
2021 -565.598
2022 -787.580 28.19%
2023 -212.647 -270.37%
2023 -1.067.514 80.08%
2024 -209.346 -409.93%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Diagnamed Holdings Corp. Operating Cashflow
Year Operating Cashflow Growth
2021 -565.598
2022 -787.580 28.19%
2023 -212.647 -270.37%
2023 -1.067.514 80.08%
2024 -209.346 -409.93%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Diagnamed Holdings Corp. Capital Expenditure
Year Capital Expenditure Growth
2021 0
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Diagnamed Holdings Corp. Equity
Year Equity Growth
2021 2.239.737
2022 1.246.056 -79.75%
2023 488.724 -154.96%
2023 235.890 -107.18%
2024 -71.488 429.97%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Diagnamed Holdings Corp. Assets
Year Assets Growth
2021 2.389.980
2022 1.615.568 -47.93%
2023 859.970 -87.86%
2023 662.270 -29.85%
2024 202.119 -227.66%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Diagnamed Holdings Corp. Liabilities
Year Liabilities Growth
2021 150.243
2022 369.512 59.34%
2023 371.246 0.47%
2023 426.380 12.93%
2024 273.607 -55.84%

Diagnamed Holdings Corp. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.01
Price to Earning Ratio
-1.31x
Price To Sales Ratio
0x
POCF Ratio
-1.23
PFCF Ratio
-0.62
Price to Book Ratio
-11.2
EV to Sales
0
EV Over EBITDA
-0.3
EV to Operating CashFlow
-0.35
EV to FreeCashFlow
-0.35
Earnings Yield
-0.76
FreeCashFlow Yield
-1.63
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0.01
Graham NetNet
-0

Income Statement Metrics

Net Income per Share
-0.01
Income Quality
1.07
ROE
-4.14
Return On Assets
-3.02
Return On Capital Employed
10.59
Net Income per EBT
1
EBT Per Ebit
0.81
Ebit per Revenue
0
Effective Tax Rate
0.31

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.01
Free CashFlow per Share
-0.01
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
7.33
Return on Tangible Assets
-3.02
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
-0
Shareholders Equity per Share
-0
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.23
Current Ratio
0.74
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
-71488
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
-8241.5
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Diagnamed Holdings Corp. Dividends
Year Dividends Growth

Diagnamed Holdings Corp. Profile

About Diagnamed Holdings Corp.

Diagnamed Holdings Corp. engages in developing a platform of software-based prescription digital therapeutic products for detecting brain age and tremors for neurological disorders. The company is headquartered in Vancouver, Canada.

CEO
Mr. Fabio Chianelli
Employee
0
Address
550 Burrard Street
Vancouver, V6C 0A3

Diagnamed Holdings Corp. Executives & BODs

Diagnamed Holdings Corp. Executives & BODs
# Name Age
1 Mr. Jing Peng C.A., C.P.A., CA, CPA, MMPA
Chief Financial Officer
70
2 Mr. Fabio Chianelli
Chairman, President & Chief Executive Officer
70
3 Mr. Andrew Newbury CPA
Corporate Secretary
70

Diagnamed Holdings Corp. Competitors

RDARS Inc. Logo
RDARS Inc.

RDRS.CN

(1.8)
Looking Glass Labs Ltd. Logo
Looking Glass Labs Ltd.

NFTX.NE

(1.0)
Québec Nickel Corp. Logo
Québec Nickel Corp.

QNI.CN

(1.5)